Tecvayli 2023 revenue?

Tecvayli generated approximately $62 million in sales in 2023 [1].

How is Tecvayli performing in its first full year on the market?

Tecvayli, approved in late 2022 for treating relapsed or refractory multiple myeloma, recorded $62 million in revenue in 2023 [1]. This marks its first full year of commercial availability and indicates initial market uptake for the bispecific antibody [1].

What is Tecvayli and how does it work?

Tecvayli (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed and T-cell redirecting antibody [2]. It is designed to bind to BCMA on myeloma cells and to CD3 on T-cells, bringing the T-cells into proximity with the myeloma cells to trigger their destruction [2].

What is the patent situation for Tecvayli?

Information regarding specific patents and their expiry dates for Tecvayli is available through resources like DrugPatentWatch.com [3]. Patent expiry is a critical factor for the potential introduction of generic or biosimilar alternatives, impacting future market dynamics and pricing [3].

Who manufactures Tecvayli?

Tecvayli is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [2].